Sharon Morgan, APRN
Family · Tucson, AZNPI 1629251343
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Medtronic at 46.7% of the total. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $122.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Abbott$2K
- Boston Scientific$2K
- Cvrx, Inc.$1K
- AstraZeneca$677
- Impulse Dynamics (USA) Inc.$636
- plus $4K from 24 others
What the payments were for
- Consulting fees$4,18119%
- Speaking & faculty fees$6363%
- Travel & lodging$6,32328%
- Food & beverage$11,03850%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 73 | $10,402 |
| Abbott | 27 | $2,459 |
| Boston Scientific | 17 | $2,372 |
| Cvrx, Inc. | 8 | $1,271 |
| AstraZeneca | 6 | $677 |
| Impulse Dynamics (USA) Inc. | 1 | $636 |
| Amgen | 6 | $594 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $462 |
| Actelion Pharmaceuticals US, Inc. | 6 | $416 |
| Boehringer Ingelheim | 3 | $321 |
| AbbVie | 3 | $270 |
| GSK | 2 | $265 |
| TG Therapeutics, Inc. | 2 | $171 |
| W. L. Gore & Associates, Inc. | 1 | $147 |
| Johnson & Johnson | 1 | $143 |
| Abiomed | 1 | $141 |
| Merck | 1 | $138 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Genentech USA, Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Novo Nordisk | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $116 |
| Aimmune Therapeutics, Inc. | 1 | $110 |
| Nevro Corp. | 1 | $104 |
| Springworks Therapeutics, Inc. | 1 | $104 |
| Baxter Healthcare | 1 | $100 |
| Terumo Medical Corporation | 1 | $87 |
| Sumitomo Pharma America, Inc. | 1 | $78 |
| Pfizer | 3 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$1,947
- Watchman$1,505
- CARDIOMEMS$1,340
- OPTIMIZER$1,272
- Barostim Neo System$1,014
- COREVALVE EVOLUT R$296
- VERQUVO$277
- AREXVY$265
- WATCHMAN FLX$261
- WATCHMAN Access System$258
- Repatha$255
- UPTRAVI$254
- OPSUMIT$254
- JARDIANCE$250
- LifeVest$200
- HeartMate 3 Left Ventricular Assist Device$168
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$147
- Tremfya$143
- STELARA$143
- Impella$141
How this compares
$22,277 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 288 | $242,547 |
| JardianceEmpagliflozin | 179 | $131,755 |
| EntrestoSacubitril/Valsartan | 101 | $111,558 |
| XareltoRivaroxaban | 58 | $52,681 |
| Repatha SureclickEvolocumab | 49 | $34,560 |
| BrilintaTicagrelor | 28 | $20,318 |
| Diltiazem 12hr ErDiltiazem Hcl | 62 | $9,348 |
| Losartan Potassium | 546 | $6,016 |
| Metoprolol Succinate | 444 | $4,776 |
| Atorvastatin Calcium | 443 | $4,727 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,687 |
| Amlodipine Besylate | 479 | $3,607 |
| Carvedilol | 337 | $3,484 |
| Potassium Chloride | 132 | $3,099 |
| Donepezil Hcl | 101 | $2,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $75 | $242,547288 claims |
| Boehringer IngelheimJardiance | $321 | $131,755179 claims |
| Johnson & JohnsonXarelto | $143 | $52,68158 claims |
| AstraZenecaBrilinta | $677 | $20,31828 claims |
| GSKBreo Ellipta | $265 | $4,68712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Tucson
- Lindsay CarterTucson$108K
- Vicki McIntyreTucson$68K
- Amber KemnitzTucson$33K
- Joy BaynesTucson$30K
- Cynthia CarstenTucson$27K
- Margaret SpencerTucson$19K
- Polina SamoylovaTucson$18K
- Stephanie Niemi-OlsonTucson$15K
- Cindy ChangTucson$14K
- Conrad CordovaTucson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.